ABCELLERA BIOLOGICS (8QQ) — Cash Flow-to-Debt Ratio
ABCELLERA BIOLOGICS (8QQ) has a Cash Flow-to-Debt Ratio of -0.09x as of December 2025, meaning its operating cash flow of €-34.74 Million could theoretically repay 0% of its total liabilities (€390.05 Million) in one year. See ABCELLERA BIOLOGICS free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ABCELLERA BIOLOGICS Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for ABCELLERA BIOLOGICS across 5 annual periods. Also explore ABCELLERA BIOLOGICS equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ABCELLERA BIOLOGICS (2021–2025)
Year-by-year debt coverage analysis for ABCELLERA BIOLOGICS. For market capitalisation and broader financial context, see 8QQ company net worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | €-131.29 Million | €390.05 Million | ▲ +5.6% |
| 2024 | -0.36x | €-108.56 Million | €304.47 Million | ▼ -172.8% |
| 2023 | -0.13x | €-43.88 Million | €335.78 Million | ▼ -114.5% |
| 2022 | 0.90x | €277.36 Million | €307.63 Million | ▲ +7.9% |
| 2021 | 0.84x | €244.58 Million | €292.84 Million | — |